Contact
info@topadur.com+41 44 755 44 66Topadur Pharma AG
Grabenstrasse 11A
8952 Schlieren, Switzerland
Grabenstrasse 11A
8952 Schlieren, Switzerland
Zurich-Schlieren, Switzerland, 2 November 2023
We are pleased to announce that TOPADUR PHARMA AG has been awarded an Innosuisse grant to fund our collaborative project with partners from Yonsei University and Juvic Inc. in South Korea. The project aims to develop new technologies for the treatment of systemic sclerosis. We thank Innosuisse and the Korea Institute for Advancement of Technology (KIAT) for their support.
TOPADUR announces the submission of an application to the European Medicines Agency to receive Orphan Drug Designation Status.
Read moreTOPADUR in collaboration with the University Hospital of Zurich and the University of Zurich was awarded CHF 859k by Innosuisse.
Read moreTopical Wound Treatment with a NO-Releasing PDE5 Inhibitor Formulation Enhances Blood Perfusion and Promotes Healing in Mice.
Read more
